SRPK2 and breast cancer: To ask if IGF-1 induces mRNA stability through SRPK2, breast cancer cells were exposed to IGF-1 with a vehicle or SRPK2 inhibitor, SRPN-340, prior to treatment with actinomycin-D, a transcriptional inhibitor, for 0, 3, and 5 hours [8].